ZBIO

Conviction 59HealthcareScan · Fri, Jun 26, 2026

ZBIO$25.83+4.70%

ResistanceSupportVol 14Insider buy

Vol MA14 1.05M

Mar 27Apr 15May 4May 20Jun 9Jun 26

Zenas BioPharma, Inc.PHARMACEUTICAL PREPARATIONSwww.zenasbio.com ↗

Price25.83

Change+4.70%

Gap-1.62%

Rel volume5.90×

Avg volume903.73K

Avg $ vol19.08M

SMA 2019.35

SMA 5019.38

SMA 20024.77

Price vs 50+33.31%

Price vs 200+4.30%

MA stackmixed

50/200 cross—

Supertrendup · 20.12

RSI (14)73

MACD hist0.82

MACD cross—

Stoch %K / %D98 / 97

ADX (14)26

+DI / −DI41 / 9

RSI divergence—

MACD divergence—

ATR %+6.06%

ADR %7.46%

52w high43.17

52w low9.14

From 52w high-40.17%

Above 52w low+182.60%

New 52w highNo

SqueezeOff

Bollinger width47.56%

%B1.20

Donchian pos98.26%

Donchian high25.99

Donchian low16.77

AVWAP (52w high)20.67

vs AVWAP high+24.97%

AVWAP (52w low)22.39

vs AVWAP low+15.35%

OBV trendUp

Chaikin MF (20)0.37

Today vs 20d5.90×

Avg vol (14d)1.05M

Avg vol (20d)903.73K

Avg $ vol (20d)19.08M

Market cap—

RS 3m (vs SPY)-0.62%

RS 6m (vs SPY)-48.94%

RS line new highNo

Trend template4/8

Technical rank58.2

1 week+30.59%

1 month+42.79%

3 months+16.56%

6 months-39.66%

1 year+153.48%

YTD-25.13%

P/E-4.13

P/B4.64

P/S155.88

P/FCF-9.04

EPS-8.44

Div yield—

ROE-112.48%

ROA-50.52%

Debt/Eq0.23

Current11.94

EV/EBITDA—

Gross margin—

Net margin—

Rev growth100.00%

EPS growth-140.62%

Price target41.40

Target upside67.68%

Analyst ratingBuy

Institutional90.03%

Ent. value1.14B

Revenue10M

Net income-80.99M

Gross profit—

Free cash flow-172.35M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out63.13M

Employees167

ListedFri, Sep 13, 2024

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeC

Conviction59 / 100

Pattern quality—

Tech rank58.2 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance21.62

Support16.59

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ZBIO

All disclosures →

No recent disclosed trades by Congress in ZBIO. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ZBIO · 5 buys

Insider	Side	Shares	Value	Traded	Filed
Allen Patricia L Director · Stock Option (Right to Buy) · 2026-06-15	Grant	18.5K	—	2026-06-15	2026-06-17
Boylan James P Director · Stock Option (Right to Buy) · 2026-06-15	Grant	18.5K	—	2026-06-15	2026-06-17
MOULDER LEON O JR Chief Executive Officer · Common Stock · 2026-05-18	Other	—	—	2026-05-18	2026-05-18
MOULDER LEON O JR Chief Executive Officer · Common Stock · 2026-05-18	Buy	60K	$1.0M	2026-05-18	2026-05-18
MOULDER LEON O JR Chief Executive Officer · Common Stock · 2026-04-29	Buy	35K	$617K	2026-04-29	2026-04-29
MOULDER LEON O JR Chief Executive Officer · Common Stock · 2026-04-28	Buy	25K	$451K	2026-04-28	2026-04-29
MOULDER LEON O JR Chief Executive Officer · Common Stock · 2026-04-28	Other	—	—	2026-04-28	2026-04-29

SEC filings

EDGAR filings in ZBIO

EDGAR →

No recent SEC filings on file for ZBIO.

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.